| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 5th June 2020 | Jarrod Longcor | 65,218 | Open or private purchase | $1.15 | $74,674.61 |
| 5th June 2020 | Dov Elefant | 4,348 | Open or private purchase | $1.15 | $4,978.46 |
| 5th June 2020 | James V Caruso | 21,740 | Open or private purchase | $1.15 | $24,892.30 |
| 4th June 2020 | Stephen A Hill | 18,000 | Open or private purchase | $1.08 | $19,438.20 |
| 3rd February 2020 | Jarrod Longcor | 40,000 | Grant/award etc. | $2.71 | $108,400.00 |
| 3rd February 2020 | Dov Elefant | 10,000 | Grant/award etc. | $2.71 | $27,100.00 |
| 3rd February 2020 | James V Caruso | 100,000 | Grant/award etc. | $2.71 | $271,000.00 |
| 28th February 2019 | Jarrod Longcor | 100 | Open or private purchase | $2.00 | $200.25 |
Cellectar Bio Sciences
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; and CLR 125, which intends to treat micro metastatic disease.
Ticker: CLRB
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1279704
Employees: 8
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Goldman Sachs to cut about 400 jobs - Bloomberg News
30th September 2020
HP to pay US$6 million fine to settle SEC charges
30th September 2020
NextEra Energy CEO rules out hostile M&A after offer to Duke Energy
30th September 2020
Alphabet Inc's Google launches Google TV, new Chromecast
30th September 2020